If you glance at a diagram of the continuum of translational research, the arrows point orderly to five phases — from basic research to improving population health.
It started at the end of a long day. Jessica Panzer, MD, PhD, then just a few weeks into her pediatric neurology residency at The Children’s Hospital of Philadelphia, was about to go home. Instead, she was called to the emergency room to consult on a 3-year-old girl who could barely walk.
The Children’s Hospital of Philadelphia and four other high-profile oncology research programs plus a coordinating center joined the new Pediatric Preclinical Testing Consortium (PPTC) launched by the National Cancer Institute (NCI) to help researchers identify drug candidates for pediatric clinical trials.
Despite advances in T-cell acute lymphoblastic leukemia treatment, between 15 and 20 percent of children who achieve an initial complete remission will relapse. They may need more intensive therapy or alternative approaches, but physicians do not yet have a reliable way of predicting which patients are at high-risk of relapse.
Colorectal cancer mainly exists in people older than 50, but it also can occur in young adults who have a genetic condition called familial adenomatous polyposis (FAP).
CHOP's Antonella Cianferoni, MD, PhD, recently received a two-year, $140,000 grant to study the genetic underpinnings of the severe food allergy eosinophilic esophagitis.
Finding out Cornelia de Lange Syndrome (CdLS) causes could be extremely important to understanding human development at all levels, which is why Ian Krantz, MD, medical director of the Center for Cornelia de Lange Syndrome and Related Diagnosis at CHOP, and his colleagues have dedicated the past two decades to research that is piecing together the basic biology of CdLS.
Cookies for Kids’ Cancer, a nonprofit foundation dedicated to pediatric cancer research, uses the proceeds from its cookie sales and other fundraising events to provide grants to support the work of scientists at five of the nation’s leading pediatric cancer centers.
A new research opportunity under development as part of its Project:EveryChild, called Project:EveryChild Pediatric MATCH, aims to use the power of precision medicine to potentially provide investigational therapies for some children with advanced cancers.
CHOP medical geneticist and researcher Ian Krantz, MD, has been a tireless detective in his efforts to find out what genetic syndrome could be behind Leta’s constellation of symptoms.
